Sustained expression of Epstein-Barr virus episomal vector mediated factor VIII in vivo following muscle electroporation

Haemophilia : the Official Journal of the World Federation of Hemophilia
W-H MeiJ Lu

Abstract

Haemophilia A treatment is an attractive candidate for gene therapy. The aim of haemophilia gene therapy is to obtain long-term therapeutic level of factor VIII (FVIII). We investigated Epstein-Barr virus (EBV)-based episomal vector combined with in vivo electroporation of naked DNA as a safe, efficient and simple method for correcting FVIII deficiency. A combinant FVIII expression EBV-based episomal vector pcDNA3-FVIII-EBVR was constructed and expressed in COS-7 cells. Then the naked plasmid DNA was injected into the quadriceps of mice following the electric pulse stimulation. Our data showed that pcDNA3-FVIII-EBVR expression in transfected COS-7 can maintain stably for at least 60 days and the hFVIII:Ag in plasma in two pcDNA3-FVIII-EBVR groups mice was higher than that in pcDNA-FVIII groups no matter with or without electric pulse stimulation. With the stimulating of electric pulse, the FVIII expression in plasma of recipient mice was increased two- to fourfolds and can be lasted for at least 90 days. No severe muscle damage was detected. So this novel strategy that FVIII expression mediated by EBV episomal vector following muscle electroporation is efficient, safe, simple and economic and may be applicable to clinical usage.

References

Apr 1, 1989·Journal of Photochemistry and Photobiology. B, Biology·A Sarasin
Jun 14, 1967·Journal of Molecular Biology·B Hirt
Apr 14, 1999·Proceedings of the National Academy of Sciences of the United States of America·L M MirD Scherman
Sep 1, 1999·Proceedings of the National Academy of Sciences of the United States of America·T VandenDriesscheM K Chuah
Jun 2, 2001·Human Gene Therapy·C G LeeM M Gottesman
Mar 7, 2003·Gene Therapy·H GollinsD J Wells
Dec 17, 2003·FEBS Letters·Kathleen Van CraenenbroeckGuy Haegeman
Jun 8, 2004·Biochemistry and Cell Biology = Biochimie Et Biologie Cellulaire·Marie-Eve HabelDaniel Jung
Jun 11, 2005·Biotechnology and Bioengineering·Rajkumar KunaparajuNoelle-Anne Sunstrom

❮ Previous
Next ❯

Citations

Feb 26, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Wen-Hsin LoYu-Chen Hu
Sep 23, 2006·Expert Opinion on Biological Therapy·Shu Uin GanRoy Y Calne
Jul 7, 2021·Nature Communications·Jin YangFrançois St-Pierre

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.